

## 5. References

- (1) Cancer Today. Available at: <https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf>. Accessed Nov 5, 2023.
- (2) Cancer Tomorrow. Available at: [https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=11&single\\_unit=50000](https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=11&single_unit=50000). Accessed Nov 5, 2023.
- (3) Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018 -11;68(6):394-424.
- (4) Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012 -03-31;379(9822):1245-1255.
- (5) Gomaa A, Khan S, Toledano M, Waked I, Taylor-Robinson S. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol* 2008 -07-21;14(27):4300-4308.
- (6) Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. *CA Cancer J Clin* 2017 -07-08;67(4):273-289.
- (7) Child CG, Turcotte JG. Surgery and portal hypertension. *Major Probl Clin Surg* 1964;1:1-85.
- (8) Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973 -08;60(8):646-649.
- (9) Norihiro Kokudo KH. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set (Sixth Edition). Volume 2 ed.; 2017.
- (10) Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. *J Hepatol* 2021 -10;75(4):960-974.
- (11) Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. *J Clin Oncol* 2020 -12-20;38(36):4317-4345.

- (12) Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. *Liver Cancer* 2021 -6;10(3):181-223.
- (13) Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020 -05-14;382(20):1894-1905.
- (14) Cheng A, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol* 2022 -04;76(4):862-873.
- (15) Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021 -03-29;372:n71.
- (16) Critical Appraisal Skills Programme checklist. Available at: [https://casp-uk.net/images/checklist/documents/CASP-Systematic-Review-Checklist/CASP-Systematic-Review-Checklist-2018\\_fillable-form.pdf](https://casp-uk.net/images/checklist/documents/CASP-Systematic-Review-Checklist/CASP-Systematic-Review-Checklist-2018_fillable-form.pdf). Accessed May 5, 2023.
- (17) D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. *Hepatology* 2022 -10;76(4):1000-1012.
- (18) Cheon J, Kim H, Kim HS, Kim CG, Kim I, Kang B, et al. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. *Ther Adv Med Oncol* 2023 January 12;15:17588359221148541.
- (19) Kulkarni AV, Krishna V, Kumar K, Sharma M, Patodiya B, Khan A, et al. Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. *J Clin Exp Hepatol* 2023;13(4):618-623.
- (20) Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C, et al. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. *Cancers (Basel)* 2022 -03-28;14(7):1722.
- (21) Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. *Hepatology* 2015 -01;61(1):184-190.
- (22) Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. *Oncology* 2010;79(1-2):27-38.

(23) Marrero JA, Kudo M, Venook AP, Ye S, Bronowicki J, Chen X, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. *J Hepatol* 2016 -12;65(6):1140-1147.

(24) Piscaglia F, Terzi E, Cucchetti A, Trimarchi C, Granito A, Leoni S, et al. Treatment of hepatocellular carcinoma in Child-Pugh B patients. *Dig Liver Dis* 2013 -10;45(10):852-858.

(25) Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. *J Hepatol* 2021 -09;75(3):600-609.